為什麼腫瘤首次人體試驗在開始前就可能失敗
關於場地組合、方案假設、啟動延遲和隱藏執行風險的觀點。
洞察
早期腫瘤開發中，哪些訊號值得先看？
這裡整理公開研究、腫瘤會議訊號和我們對 FIH 執行風險的觀點。Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方來源會作為可篩選的資訊補充，所有卡片保留原始公開連結。
重点观点
先看那些申办方通常发现得太晚的问题。
这些固定主题让洞察页先有清楚判断：外部公开来源能同步时作为补充，不能同步时页面也不会变成空的信息库。
場地級啟動風險與傳統可行性評估
為什麼平均值和聲譽型專家選擇可能錯過真正重要的執行尾部風險。
中國創新藥如何進入全球開發語境
全球開發策略、區域選擇和試驗設計如何影響中國以外市場的可信度。
腫瘤場地選擇應如何按機制區分
ADC、雙抗、KRAS、CAR-T、放射性配體、DDR 資產和 TKI 不應使用同一套場地邏輯。
公開資訊庫
公開研究與腫瘤會議訊號
把 Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方公開來源放在同一個列表裡。可按來源、主題和關鍵詞篩選；所有卡片只保留公開後設資料和官方原始連結。
當前來源：全部來源 · 主題：Program · 6 條 · 每頁 10 條
Closing Plenary Session examined highlights from the AACR Annual Meeting 2026 - AACR Annual Meeting News
Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Fifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape - AACR Annual Meeting News
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
Final New Drugs on the Horizon session completed the series with the last four novel molecules - AACR Annual Meeting News
Presenters described a first-in-class inhibitor of cyclin A/B-substrate interaction, a molecular glue degrader for the treatment of acute myeloid leukemia, a novel antibody-drug conjugate, and a dual T-cell ag... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
Fourth Plenary Session explored generational trends and possible drivers of early-onset cancers - AACR Annual Meeting News
Andrew T. Chan, MD, MPH, chaired the session, which examined the rising incidence of early-onset cancers and the potential contributions of obesity, bacterial exposures, and weaning to this trend. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Second New Drugs on the Horizon session featured first disclosure of four more innovative therapeutics - AACR Annual Meeting News
The session spotlighted a human-sialidase-armed antitumor antibody, a novel CDK2 inhibitor, a molecular glue degrader, and a dual-payload antibody-drug conjugate. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Third Clinical Trials Plenary Session delved into next-generation cellular therapies and immunotherapies - AACR Annual Meeting Ne...
Omar Nadeem, MD, discussed results of the CAR-PRISM trial, which evaluated the use of ciltacabtagene autoleucel in patients with high-risk smoldering myeloma, an early, asymptomatic form of multiple myeloma. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源